| 1 |
33772142 | PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway. | 2022 Jan |
1 |
| 2 |
35301287 | Claudin1 decrease induced by 1,25-dihydroxy-vitamin D3 potentiates gefitinib resistance therapy through inhibiting AKT activation-mediated cancer stem-like properties in NSCLC cells. | 2022 Mar 18 |
3 |
| 3 |
35399731 | LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma. | 2022 |
1 |
| 4 |
32894437 | Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP). | 2021 Feb |
2 |
| 5 |
33491264 | RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma. | 2021 Mar |
2 |
| 6 |
33529999 | A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC). | 2021 Feb |
1 |
| 7 |
33868471 | Lentivirus-mediated silencing of CNTN1 enhances gefitinib sensitivity by reversing epithelial-mesenchymal transition in lung adenocarcinoma A549 cells. | 2021 Jun |
1 |
| 8 |
33980216 | Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells. | 2021 May 12 |
3 |
| 9 |
34267282 | Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells. | 2021 Jul 15 |
1 |
| 10 |
34335947 | Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment. | 2021 |
1 |
| 11 |
34358366 | Effect of tyrosine kinase inhibitors on cell migration and epithelial-to-mesenchymal transition in Asian head and neck cancer cell lines. | 2021 Nov |
1 |
| 12 |
34389432 | A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis. | 2021 Nov 1 |
2 |
| 13 |
34510760 | Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer. | 2021 Oct |
1 |
| 14 |
34543169 | Yang-Yin-Jie-Du decoction overcomes gefitinib resistance in non-small cell lung cancer via down-regulation of the PI3K/Akt signalling pathway. | 2021 Dec |
1 |
| 15 |
34581421 | RHBDD1 promotes proliferation, migration, invasion and EMT in renal cell carcinoma via the EGFR/AKT signaling pathway. | 2021 Dec |
1 |
| 16 |
34646330 | Qing-Kai-Ling Injection Acts Better Than Shen-Fu Injection in Enhancing the Antitumor Effect of Gefitinib in Resistant Non-Small Cell Lung Cancer Models. | 2021 |
1 |
| 17 |
34681198 | Synthesis and Biological Evaluation of (S)-2-(Substituted arylmethyl)-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide Analogs and Their Synergistic Effect against PTEN-Deficient MDA-MB-468 Cells. | 2021 Sep 25 |
1 |
| 18 |
34693451 | Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway. | 2021 Dec 8 |
2 |
| 19 |
34766965 | Delivery of gefitinib in synergism with thymoquinone via transferrin-conjugated nanoparticle sensitizes gefitinib-resistant non-small cell lung carcinoma to control metastasis and stemness. | 2021 Dec 7 |
1 |
| 20 |
32004572 | ID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent necroptosis. | 2020 Apr 10 |
1 |
| 21 |
32489321 | Fuzheng Kang-Ai decoction enhances the effect of Gefitinib-induced cell apoptosis in lung cancer through mitochondrial pathway. | 2020 |
1 |
| 22 |
32552611 | Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer. | 2020 Jan-Dec |
1 |
| 23 |
32820249 | MiR-450a-5p strengthens the drug sensitivity of gefitinib in glioma chemotherapy via regulating autophagy by targeting EGFR. | 2020 Sep |
1 |
| 24 |
32895203 | [Gefitinib inhibits glycolysis and induces programmed cell death in non-small cell lung cancer cells]. | 2020 Jun 30 |
2 |
| 25 |
32956565 | M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib-resistant cell lines HCC827/GR. | 2020 Nov |
3 |
| 26 |
32963612 | Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells in vitro. | 2020 Nov |
2 |
| 27 |
30660770 | A large scale proteome analysis of the gefitinib primary resistance overcome by KDAC inhibition in KRAS mutated adenocarcinoma cells overexpressing amphiregulin. | 2019 Mar 20 |
1 |
| 28 |
30701693 | Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498. | 2019 Apr |
2 |
| 29 |
30993382 | Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo. | 2019 Jun |
1 |
| 30 |
31132355 | Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC. | 2019 Aug 5 |
1 |
| 31 |
31196210 | Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death. | 2019 Jun 13 |
1 |
| 32 |
31310954 | An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer. | 2019 Oct |
2 |
| 33 |
29215723 | High cholesterol in lipid rafts reduces the sensitivity to EGFR-TKI therapy in non-small cell lung cancer. | 2018 Sep |
1 |
| 34 |
29269300 | MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7. | 2018 Jan 22 |
1 |
| 35 |
29344641 | Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells. | 2018 Mar |
1 |
| 36 |
29480364 | Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells. | 2018 Apr |
1 |
| 37 |
29487526 | Silencing of Long Non-coding RNA MIAT Sensitizes Lung Cancer Cells to Gefitinib by Epigenetically Regulating miR-34a. | 2018 |
2 |
| 38 |
29568946 | Gefitinib inhibits malignant melanoma cells through the VEGF/AKT signaling pathway. | 2018 May |
3 |
| 39 |
29637613 | Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib. | 2018 Aug |
2 |
| 40 |
29928355 | Exosome-mediated gefitinib resistance in lung cancer HCC827 cells via delivery of miR-21. | 2018 Jun |
1 |
| 41 |
30106149 | Geranylgeranyl transferase 1 inhibitor GGTI‑298 enhances the anticancer effect of gefitinib. | 2018 Oct |
1 |
| 42 |
27930974 | miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1. | 2017 Jan |
3 |
| 43 |
28093061 | Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway. | 2017 |
2 |
| 44 |
28529576 | Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway. | 2017 May |
3 |
| 45 |
28577939 | Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines. | 2017 Jul |
1 |
| 46 |
28713965 | Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway. | 2017 Sep |
2 |
| 47 |
28828595 | The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro. | 2017 Dec |
1 |
| 48 |
28881753 | siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells. | 2017 Aug 8 |
1 |
| 49 |
29033690 | Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells. | 2017 |
1 |
| 50 |
29080795 | PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway. | 2017 Dec 15 |
1 |